|
| Wednesday, August 28, 2019 |
|
|
Eisai Enters Into Business Alliance With Cogstate for Exclusive Development and Commercialization of a Digital Tool for Self-Assessment of Cognitive Function in Japan |
| Eisai Co., Ltd. has entered into a business alliance agreement for exclusive development and commercialization of a cognitive function test - Cogstate Brief Battery (CBB) - developed by Cogstate Ltd., in Japan as a digital tool for self-assessment of cognitive function (classified as miscellaneous goods). more info >> |
|
| Tuesday, August 27, 2019 |
|
|
Eisai Provides Tanks to Supply Clean Water to Neglected Tropical Diseases Endemic Regions in Kenya, in Collaboration With Merck |
| Eisai Co., Ltd. announced that it provides tanks to supply clean water for the neglected tropical diseases (NTDs) measuresto the endemic regions in Kenya in collaboration with Merck. more info >> |
|
| Thursday, August 1, 2019 |
|
|
Eisai to Refresh and Launch Sahne Cream After 20 Years with Mild Scent and New Package |
| Eisai Co., Ltd. announced today that it refresh its SAHNE CREAM (quasi-drug) which has been widely used as medical skin care, for the first time in 20 years, and launch at pharmacies and drug stores in Japan on today August 1, 2019. more info >> |
|
| Tuesday, July 23, 2019 |
|
|
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA |
| This is the third Breakthrough Therapy designation for the LENVIMA plus KEYTRUDA combination. more info >> |
|
| Friday, July 19, 2019 |
|
|
Eisai Presented Latest Trends of Treatment for Alzheimer's at AAIC 2019 |
| Eisai Co.,Ltd. announced the presentation and discussion about the treatment, including oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat research data on Alzheimer's disease(AD). more info >> |
|
|
Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019 |
| Eisai Co.,Ltd. announced that data relating to a new anti-tau antibody E2814(1) was presented at the Alzheimer's Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019 (Poster Presentation No.: P4-696). more info >> |
|
| Thursday, July 18, 2019 |
|
|
Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019 |
| Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation. more info >> |
|
|
Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019 |
| Eisai Co.,Ltd. announced its latest data of nonclinical research which examined the effect to the synaptic function in the brain by spinal densities in regard to oral BACE (beta-site amyloid precursor protein cleaving enzyme) inhibitor elenbecestat were presented at AAIC. more info >> |
|
| Wednesday, July 17, 2019 |
|
|
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China |
| Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the China National Medical Products Administration (NMPA). more info >> |
|
| Thursday, July 11, 2019 |
|
|
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 18th consecutive year since its initial inclusion in 2002. more info >> |
|
|
|
